HUMA News and Press, Humacyte Inc. From 12/16/25

DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Oppo...

– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – – Positive outcomes for dialysis patients suffering from Steal syndrome...

DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the details of six presentations on the Company’s acellular ...

2025-11-12 12:22:21 ET More on Humacyte Humacyte, Inc. (HUMA) Q3 2025 Earnings Call Transcript Humacyte: Shares Tank On Fundraising News - What You Need To Know Humacyte Q3 2025 Earnings Preview Humacyte shares sink as it announces pricing of $60M direct offe...

2025-11-12 12:21:36 ET Humacyte, Inc. (HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Laura Niklason - Founder, President, CEO & Director Dale Sander - CFO, Chief Corporate Development Officer & Treasurer ... Read the ful...

DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB: KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB: KBL...

2025-11-12 09:28:49 ET DENVER, Colo., Nov 12, 2025 ( 247marketnews.com )- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kr...

2025-11-12 07:29:14 ET More on Humacyte Humacyte: Shares Tank On Fundraising News - What You Need To Know Humacyte Q3 2025 Earnings Preview Humacyte shares sink as it announces pricing of $60M direct offering Seeking Alpha’s Quant Rating on Humacyte ...

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surger...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...